Mylan NV, whose price increases on its lifesaving EpiPen drug drew broad criticism this summer and helped launched a federal investigation, on Friday said it had launched its half-priced generic version of the medicine.
from WSJ.com: US Business http://ift.tt/2hGsVb3
via IFTTT
No comments:
Post a Comment